Advisory Alpha LLC Makes New $260,000 Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Advisory Alpha LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,815 shares of the biopharmaceutical company’s stock, valued at approximately $260,000.

A number of other large investors have also modified their holdings of GILD. Public Sector Pension Investment Board grew its stake in shares of Gilead Sciences by 72.9% during the second quarter. Public Sector Pension Investment Board now owns 47,722 shares of the biopharmaceutical company’s stock worth $3,274,000 after acquiring an additional 20,120 shares during the last quarter. Marshall Wace LLP purchased a new stake in Gilead Sciences in the second quarter valued at approximately $8,269,000. Insigneo Advisory Services LLC boosted its position in Gilead Sciences by 1.7% in the second quarter. Insigneo Advisory Services LLC now owns 8,830 shares of the biopharmaceutical company’s stock valued at $661,000 after buying an additional 148 shares during the last quarter. Point72 Asset Management L.P. boosted its position in Gilead Sciences by 43.2% in the second quarter. Point72 Asset Management L.P. now owns 512,125 shares of the biopharmaceutical company’s stock valued at $35,137,000 after buying an additional 154,525 shares during the last quarter. Finally, Fred Alger Management LLC boosted its position in Gilead Sciences by 9.8% in the second quarter. Fred Alger Management LLC now owns 27,357 shares of the biopharmaceutical company’s stock valued at $1,877,000 after buying an additional 2,442 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now owns 138,919 shares in the company, valued at $12,886,126.44. The trade was a 64.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 456,234 shares of company stock worth $42,130,461. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Down 0.1 %

Shares of GILD stock opened at $92.92 on Friday. The stock’s fifty day moving average is $91.63 and its two-hundred day moving average is $84.63. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The firm has a market capitalization of $115.80 billion, a P/E ratio of 1,032.44, a PEG ratio of 1.31 and a beta of 0.18. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.29 EPS. Research analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a $0.77 dividend. The ex-dividend date was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.31%. Gilead Sciences’s payout ratio is currently 3,422.22%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GILD. The Goldman Sachs Group upped their target price on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Sanford C. Bernstein began coverage on Gilead Sciences in a research report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 target price on the stock. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Royal Bank of Canada reiterated a “sector perform” rating and issued a $84.00 target price on shares of Gilead Sciences in a research report on Wednesday, December 11th. Finally, Robert W. Baird upped their price objective on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.